ATELLICA™ IM COMPLEXED PROSTATE-SPECIFIC ANTIGEN - COFEPRIS Registration 506R2019 SSA
Access comprehensive regulatory information for ATELLICA™ IM COMPLEXED PROSTATE-SPECIFIC ANTIGEN (ATELLICA™ IM COMPLEXED PROSTATE-SPECIFIC ANTIGEN) in the Mexico medical device market through Pure Global AI's free database. This Clase II medical device is registered under COFEPRIS analysis ID 506R2019 SSA and manufactured by SIEMENS HEALTHCARE DIAGNOSTICS, S. DE R.L DE C.V.. The device was registered on March 12, 2019.
This page provides complete registration details including product type (III. DIAGNOSTIC AGENTS), manufacturer information, and regulatory compliance data from the official Mexico COFEPRIS medical device database. Pure Global AI offers free access to Mexico's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate COFEPRIS regulations efficiently.
EL ENSAYO ATELLICA™ IM COMPLEXED PROSTATE-SPECIFIC ANTIGEN (ATELLICA™ IM CPSA) ESTÁ PREVISTO PARA USO DIAGNÓSTICO IN VITRO EN LA DETERMINACIÓN CUANTITATIVA DE ANTÍGENO PROSTÁTICO ESPECÍFICO UNIDO (CPSA) EN SUERO HUMANO.
THE ATELLICA IM COMPLEXED PROSTATE-SPECIFIC ANTIGEN ASSAY (ATELLICA™™ IM CPSA) IS INTENDED FOR IN VITRO DIAGNOSTIC USE IN THE QUANTITATIVE DETERMINATION OF BOUND PROSTATE-SPECIFIC ANTIGEN (CPSA) IN HUMAN SERUM.